Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

793
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

711
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
711
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

472
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
472
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

440
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
440

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrical and Structural Atrial Remodeling Identifies a High-Risk Phenotype in Embolic Stroke of Undetermined Source.

JACC. Advances·2026
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.

Deutsches Arzteblatt international·2026
Same author

Relationship between culprit lesion high-risk plaque features and adverse cardiovascular outcome at two years follow-up in patients with acute coronary syndrome. Insights from the OPTICO-ACS study.

The international journal of cardiovascular imaging·2026
Same author

Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.

European journal of heart failure·2026
Same author

Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.

ESC heart failure·2026

Related Experiment Video

Updated: Apr 15, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.8K

Peripartum cardiomyopathy: current management and future perspectives.

Denise Hilfiker-Kleiner1, Arash Haghikia2, Justus Nonhoff2

  • 1Department of Cardiology and Angiology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany hilfiker.denise@mh-hannover.de.

European Heart Journal
|February 1, 2015
PubMed
Summary

Peripartum cardiomyopathy (PPCM) is a severe heart condition during pregnancy. This review explores PPCM

Keywords:
Heart failurePeripartum cardiomyopathyPregnancy

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.8K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K

Area of Science:

  • Cardiovascular Physiology and Pathology
  • Maternal-Fetal Medicine
  • Cardiomyopathy Research

Background:

  • Pregnancy induces significant cardiovascular changes, increasing risks for complications.
  • Peripartum cardiomyopathy (PPCM) is a critical heart disease developing late in pregnancy or postpartum.
  • Distinguishing PPCM symptoms from normal pregnancy discomforts and other conditions like preeclampsia is challenging.

Purpose of the Study:

  • To review novel physiological and pathophysiological aspects of the maternal cardiovascular system in PPCM.
  • To compare normal pregnancy, hypertensive disorders, genetic factors, and infections in PPCM.
  • To highlight current clinical and basic science knowledge, focusing on diagnostic and therapeutic advancements.

Main Methods:

  • Review of current clinical and basic science data on peripartum cardiomyopathy.
  • Comparative analysis of cardiovascular changes in normal pregnancy versus PPCM.
  • Examination of PPCM in the context of hypertensive complications, genetic predispositions, and infectious diseases.

Main Results:

  • PPCM diagnosis is complicated by overlapping symptoms with normal pregnancy and other pathologies.
  • Underlying pathophysiologies, biomarkers, and treatment options for PPCM remain poorly understood.
  • Emerging data on long-term prognosis and management, including subsequent pregnancies, are becoming available.

Conclusions:

  • Further research is needed to elucidate PPCM's pathophysiology and improve diagnostic accuracy.
  • Novel insights into diagnostic tools and therapeutic strategies offer promise for PPCM management.
  • Comprehensive understanding and management protocols are crucial for improving outcomes in PPCM patients.